Key Insights

Highlights

Success Rate

76% trial completion

Published Results

29 trials with published results (9%)

Research Maturity

91 completed trials (28% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.8%

29 terminated out of 329 trials

Success Rate

75.8%

-10.7% vs benchmark

Late-Stage Pipeline

4%

14 trials in Phase 3/4

Results Transparency

32%

29 of 91 completed with results

Key Signals

29 with results76% success29 terminated

Data Visualizations

Phase Distribution

233Total
Not Applicable (81)
Early P 1 (7)
P 1 (85)
P 2 (46)
P 3 (12)
P 4 (2)

Trial Status

Recruiting98
Completed91
Unknown46
Active Not Recruiting29
Terminated29
Withdrawn19

Trial Success Rate

75.8%

Benchmark: 86.6%

Based on 91 completed trials

Clinical Trials (329)

Showing 20 of 20 trials
NCT04123574Early Phase 1Withdrawn

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

NCT04594772Phase 2Active Not RecruitingPrimary

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

NCT06242470Phase 1Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT01915225Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

NCT06276764Enrolling By Invitation

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

NCT07653594Not ApplicableNot Yet Recruiting

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

NCT07732686Not Yet RecruitingPrimary

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT06593431Phase 3RecruitingPrimary

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

NCT03410030Phase 1Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT06545942Phase 1Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT02905578Phase 2Completed

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

NCT04970056RecruitingPrimary

Pancreatic Cancer Early Detection Consortium

NCT04263948Not ApplicableCompletedPrimary

Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform

NCT03716531Not ApplicableActive Not RecruitingPrimary

Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement

NCT06580002Phase 2Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT07700992Recruiting

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

NCT07612046Recruiting

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

NCT06282809Not ApplicableRecruitingPrimary

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

NCT07671937Not ApplicableNot Yet Recruiting

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

NCT07022015Not ApplicableRecruitingPrimary

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

Scroll to load more

Research Network

Activity Timeline